Price T Rowe Associates Inc Aldeyra Therapeutics, Inc. Transaction History
Price T Rowe Associates Inc
- $867 Billion
- Q4 2024
A detailed history of Price T Rowe Associates Inc transactions in Aldeyra Therapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 32,105 shares of ALDX stock, worth $214,461. This represents 0.0% of its overall portfolio holdings.
Number of Shares
32,105
Previous 55,622
42.28%
Holding current value
$214,461
Previous $300,000
46.33%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding ALDX
# of Institutions
128Shares Held
37.6MCall Options Held
757KPut Options Held
539K-
Perceptive Advisors LLC New York, NY9.28MShares$62 Million1.54% of portfolio
-
Knoll Capital Management, LLC Miami, FL5.48MShares$36.6 Million17.63% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.76MShares$25.1 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.62MShares$24.2 Million0.0% of portfolio
-
Kennedy Capital Management, Inc. St Louis, MO1.47MShares$9.81 Million0.17% of portfolio
About Aldeyra Therapeutics, Inc.
- Ticker ALDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,323,100
- Market Cap $390M
- Description
- Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...